{'52WeekChange': -0.3944844,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Zernikedreef 9',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.1,
 'askSize': 1100,
 'averageDailyVolume10Day': 222050,
 'averageVolume': 155452,
 'averageVolume10days': 222050,
 'beta': 0.522128,
 'beta3Year': None,
 'bid': 4.55,
 'bidSize': 800,
 'bookValue': 3.087,
 'category': None,
 'circulatingSupply': None,
 'city': 'Leiden',
 'companyOfficers': [],
 'country': 'Netherlands',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.09,
 'dayLow': 4.94,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 252331552,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.558857,
 'fiftyTwoWeekHigh': 10.98,
 'fiftyTwoWeekLow': 4.46,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 37063758,
 'forwardEps': -2.05,
 'forwardPE': -2.4634147,
 'fromCurrency': None,
 'fullTimeEmployees': 154,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.085559994,
 'heldPercentInstitutions': 0.74075997,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/proqr.com',
 'longBusinessSummary': 'ProQR Therapeutics N.V., a biopharmaceutical company, '
                        'engages in the discovery and development of RNA-based '
                        'therapeutics for the treatment of genetic disorders. '
                        'It is primarily developing sepofarsen that is in '
                        "phase II/III illuminate trial for treating leber's "
                        'congenital amaurosis 10 disease; QR-421a, which is in '
                        'phase 1/2 stellar trial for usher syndrome type 2 and '
                        'non-syndromic retinitis pigmentosa; QR-1123 that is '
                        'in phase 1/2 aurora trial for the treatment of '
                        'autosomal dominant retinitis pigmentosa; and QR-504a, '
                        'which is in first clinical trial for the treatment of '
                        'fuchs endothelial corneal dystrophy. It has a license '
                        'agreement with General Hospital Corporation, Radboud '
                        'University Medical Center, Inserm Transfert SA, and '
                        'Leiden University Medical Center. ProQR Therapeutics '
                        'N.V. was founded in 2012 and is headquartered in '
                        'Leiden, the Netherlands.',
 'longName': 'ProQR Therapeutics N.V.',
 'market': 'us_market',
 'marketCap': 252331344,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_224193775',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.04,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '31 88 166 7000',
 'previousClose': 5.1,
 'priceHint': 2,
 'priceToBook': 1.6358926,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.09,
 'regularMarketDayLow': 4.94,
 'regularMarketOpen': 5.04,
 'regularMarketPreviousClose': 5.1,
 'regularMarketPrice': 5.04,
 'regularMarketVolume': 116426,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 49966600,
 'sharesPercentSharesOut': 0.0126,
 'sharesShort': 628513,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 381235,
 'shortName': 'ProQR Therapeutics N.V.',
 'shortPercentOfFloat': 0.0156,
 'shortRatio': 4.39,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'PRQR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.308,
 'twoHundredDayAverage': 6.301727,
 'volume': 116426,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.proqr.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '2333 Ck'}